The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome a Cholestatic Liver Disease
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to evaluate the effect of LUM001 compared to placebo (looks like medicine but does not contain any medicine) on pruritus (itching) in children with Alagille Syndrome.
Description
The purpose of this study to investigate the effects of LUM001 compared to placebo on pruritus, serum bile acids, liver enzymes and other biochemical markers associated with cholestatic liver disease, during daily dosing over a 13 week period.
Details
| Condition | Alagille syndrome |
|---|---|
| Age | 1years - 18years |
| Clinical Study Identifier | TX6883 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.